OncoMethylome Sciences Expands its Collaboration with Schering-Plough
The new agreement creates a framework for OncoMethylome to provide further MGMT methylation testing to Schering-Plough. OncoMethylome currently provides this service for a multi-center clinical trial that is supported by Schering-Plough. The trial evaluates whether patients with glioblastoma multiforme, a type of brain tumor, can benefit from a more intensive temozolomide drug treatment regimen. MGMT methylation is being tested in this study for all patients' tumors.
The MGMT gene is a biomarker that has been shown to be methylated in a number of cancer types. OncoMethylome owns a patent-protected assay for determining the methylation status of the MGMT gene. Under the terms of the new agreement, OncoMethylome's assay will be used for MGMT methylation testing in multiple national and international clinical trials involving temozolomide in brain cancer and other cancers.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.